In the Abstract:

Please insert new Abstract on a separate sheet after the claim pages of the application (or to replace the previously submitted Abstract).

In the Specification:

Please amend the specification as follows:

Please amend the specification by replacing the paragraph on page 1, lines 4-9, with the following paragraph:

A2

This application is a continuation-in-part of United States Application Serial No. 08/038,596, filed March 26, 1993, now abandoned, which is a continuation-in-part of United States Application Serial No. 07/975,750, filed November 13, 1992, now abandoned, both of which are incorporated by reference herein in their entirety.

In the Claims:

Kindly cancel claims 1-35 and 44-46 are canceled without prejudice or disclaimer as being directed to non-elected subject matter.

In accordance with 37 CFR § 1.121, please substitute for claims 36-43, the following rewritten versions of the same claims, as amended. The changes are shown explicitly in the attached "Marked Up Version Showing Changes Made."

A3

36. (Amended) A recombinant vector comprising a nucleotide sequence that encodes a truncated Flk-1 having a functional Flk-1 extracellular and transmembrane domain which inhibits the cellular effects of VEGF binding.

37. (Amended) The recombinant vector of claim 36 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

38. (Amended) The recombinant vector of claim 36 in which the vector is a retrovirus vector, an adeno-associated viral vector and a herpes viral vector.

39. (Amended) The recombinant vector of claim 38 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

40. (Amended) An engineered cell line that comprises the recombinant vector of claim 36 and expresses truncated Flk-1.

A3

41. (Amended) An engineered cell line that comprises the recombinant vector of claim 38 or 39 and produces infectious retrovirus particles encoding truncated Flk-1, wherein said cell line expresses truncated Flk-1.

CONT.

42. (Amended) A recombinant truncated Flk-1 receptor protein having a functional Flk-1 extracellular and transmembrane domain, wherein said protein inhibits the cellular effects of VEGF binding.

43. (Amended) A method of inhibiting the cellular effects of VEGF in a mammal comprising administering to the mammal an effective amount of truncated Flk-1 receptor protein which inhibits the cellular effects of VEGF binding.

Kindly add the following new claims:

A4

47. (New) The recombinant truncated Flk-1 receptor protein of claim 42 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1.

48. (New) The recombinant truncated Flk-1 receptor protein of claim 42 comprising a nucleotide sequence encoding amino acids 1 through 806 of Flk-1 but lacking the 561 COOH-terminal amino acids of the intracellular kinase domain of Flk-1.

49. (New) The method of claim 43, wherein said truncated Flk-1 receptor protein has a functional Flk-1 extracellular and transmembrane domain.